Zhongzhi Pharmaceutical Holdings Limited (3737) AI Stock Analysis

• Market Cap: HK$643.72M
• Dividend Yield: 9.43%
• Average Volume (3M): 412.77K
• Price to Earnings (P/E): 20.1
• Beta (1Y): 0.04
• Revenue Growth: -1.99%
• EPS Growth: -81.52%
• Country: HK
• Employees: 2,577
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.01
• Shares Outstanding: 863,600,000
• 10 Day Avg. Volume: 391,300
• 30 Day Avg. Volume: 412,766
• PEG Ratio: -0.20
• Price to Book (P/B): 0.70
• Price to Sales (P/S): 0.35
• P/FCF Ratio: 19.84
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 68 Neutral
• Price Target: HK$0.75 ▼(-14.55% Downside)
• Action: Downgraded Date: 01/07/26
• Date: Action: Downgraded 01/07/26

The score is primarily supported by solid financial positioning (strong revenue growth and a robust, low-leverage balance sheet). Offsetting this are weaker quality signals from declining margins and volatile/negative free cash flow, plus technical overbought conditions and a relatively high P/E despite a strong dividend yield.

Positive Factors

Robust balance sheet

A consistently high equity ratio and low debt-to-equity (~0.20) provide durable financial flexibility. This capital structure supports continued R&D, manufacturing investment, and dividend payments while allowing the company to absorb industry shocks and pursue opportunistic M&A without immediate financing strain.

High gross margins

Sustained gross margins above 57% indicate efficient cost of goods sold and potential pricing power in specialty & generic drugs. High base gross profitability gives room to withstand rising SG&A or input costs and supports long-term operating leverage as revenues scale.

Multi-year revenue growth

Meaningful revenue expansion over several years signals durable market demand and successful commercial execution. Growing top-line provides scale to spread fixed costs, fund product development, and deepen customer relationships, strengthening competitive position over the medium term.

Negative Factors

Declining profitability margins

Material erosion in net and operating margins points to structural cost pressures, pricing erosion, or rising SG&A. Persistently lower margins compress retained earnings and ROE, reducing reinvestment capacity and the firm's ability to sustain dividends or fund growth without improving operational efficiency.

Volatile and negative free cash flow

Inconsistent and recently negative free cash flow undermines the company's ability to self-fund capex, R&D, and dividends. Over the medium term this raises reliance on external financing despite low leverage, increasing execution risk if cash generation does not stabilize.

Declining cash and ROE

A shrinking cash buffer combined with falling ROE signals weakening profitability efficiency and liquidity headroom. This persistent deterioration can constrain strategic flexibility, slow investment cadence, and elevate vulnerability to adverse industry or regulatory shocks over the next several quarters.

Zhongzhi Pharmaceutical Holdings Limited Business Overview & Revenue Model

Company Description

Zhongzhi Pharmaceutical Holdings Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company operates through three segments: Pharmaceutical Manufacturing, Operation of Chain Pharmacies, and Operation of On-Line Pharmacies. It provides Chinese patent medicines and decoction pieces under the Zeus, Liumian, and Caojinghua brands. The company is also manufacture and sale of food and Chinese herbs; property management; and pharmaceutical drugs, as well as offers detection and testing services. As of December 31, 2021, it operated 398 self-operated chain pharmacies, including 361 medical insurance designated pharmacies located in Zhongshan in the Guangdong Province under the Zeus brand. The company was founded in 1993 and is headquartered in Zhongshan, the People's Republic of China. Zhongzhi Pharmaceutical Holdings Limited is a subsidiary of Crystal Talent Investment Group Limited.

How the Company Makes Money

Zhongzhi Pharmaceutical Holdings Limited generates revenue through several key streams. Primarily, the company earns income by selling its pharmaceutical products, which include a range of prescription and over-the-counter medications. The company's revenue model is supplemented by partnerships with healthcare institutions and distributors that enhance market reach and product availability. Additionally, Zhongzhi may engage in research collaborations and licensing agreements with other pharmaceutical firms, allowing it to monetize its intellectual property and innovations. The company's strategic focus on both traditional Chinese medicine and Western pharmaceutical products positions it to capture diverse market segments, contributing to its overall earnings.

Zhongzhi Pharmaceutical Holdings Limited Financial Statement Overview

Summary

Strong revenue growth and a robust, low-leverage balance sheet support the score, but declining profitability (lower net/EBIT/EBITDA margins) and volatile/negative recent free cash flow weigh on financial quality.

Income Statement

Zhongzhi Pharmaceutical Holdings Limited has shown consistent revenue growth, with a notable increase from 1,342 million HKD in 2019 to 2,215 million HKD in 2024. Gross profit margin remains strong, averaging above 57%, indicating efficient cost management. However, net profit margin has declined from 8.6% in 2020 to 4.3% in 2024, suggesting increased expenses or pricing pressures. The EBIT and EBITDA margins have also weakened slightly over the years.

Balance Sheet

The company's balance sheet is robust, with a healthy equity ratio consistently above 50%, indicating a strong capital base. The debt-to-equity ratio has remained low, averaging around 0.20, suggesting prudent leverage. However, the decline in cash and cash equivalents over the years could be a concern for liquidity. Return on equity has decreased, reflecting the decline in net income.

Cash Flow

Cash flow analysis reveals volatility, with free cash flow experiencing negative values in recent years, indicating potential cash management issues. Operating cash flow has fluctuated significantly, and the free cash flow to net income ratio has been inconsistent, pointing to operational challenges in converting profits into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.01B	2.21B	2.05B	1.83B	1.75B	1.60B
Gross Profit	1.14B	1.29B	1.22B	1.07B	1.06B	991.09M
EBITDA	73.84M	170.39M	317.53M	153.87M	119.71M	203.69M
Net Income	20.55M	95.21M	162.78M	106.39M	52.13M	138.53M
Balance Sheet
Total Assets	1.84B	1.99B	1.79B	1.88B	1.52B	1.42B
Cash, Cash Equivalents and Short-Term Investments	176.31M	167.10M	166.65M	419.36M	242.18M	311.04M
Total Debt	139.50M	188.60M	225.06M	170.86M	175.74M	187.90M
Total Liabilities	752.07M	865.58M	739.30M	869.31M	622.94M	598.76M
Stockholders Equity	1.09B	1.12B	1.05B	1.00B	898.74M	820.18M
Cash Flow
Free Cash Flow	133.61M	39.62M	-69.93M	196.17M	-7.47M	-20.81M
Operating Cash Flow	197.40M	181.48M	101.50M	284.57M	178.38M	93.18M
Investing Cash Flow	-87.27M	-120.06M	-202.76M	13.38M	-135.98M	-250.42M
Financing Cash Flow	-126.94M	-58.73M	-154.62M	-68.14M	-40.83M	-71.93M

Zhongzhi Pharmaceutical Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.88
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3737, the sentiment is Positive. The current price of 0.88 is above the 20-day moving average (MA) of 0.75, above the 50-day MA of 0.72, and above the 200-day MA of 0.73, indicating a bullish trend. The MACD of 0.01 indicates Positive momentum. The RSI at 52.93 is Neutral, neither overbought nor oversold. The STOCH value of 34.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:3737.

Zhongzhi Pharmaceutical Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0239	74 Outperform	HK$726.12M	4.94	9.88%	7.52%	-24.96%	-26.43%
3737	68 Neutral	HK$643.72M	20.07	1.87%	9.43%	-1.99%	-81.52%
0950	64 Neutral	HK$789.04M	6.31	5.44%	2.92%	19.80%	55.09%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
1652	49 Neutral	HK$786.69M	-2.84	-48.86%	―	-43.46%	-96.48%
0897	46 Neutral	HK$365.66M	43.63	-1.16%	7.50%	59.60%	-351.02%
1498	41 Neutral	HK$165.83M	-2.22	-33.22%	―	-17.32%	55.74%

Zhongzhi Pharmaceutical Holdings Limited Corporate Events

Zhongzhi Pharmaceutical Flags Over 70% Profit Slump on Policy-Driven Sales Hit

Zhongzhi Pharmaceutical Holdings Limited has warned investors that its net profit for the year ended 31 December 2025 is expected to decline by more than 70% compared with 2024, based on a preliminary review of its unaudited consolidated management accounts. The company attributed the sharp earnings drop mainly to short-term sales revenue pressure stemming from adjustments to industry policies, which have weighed on profitability, but said it will continue to invest in market development and actively seek new business growth drivers, while advising shareholders and potential investors to exercise caution in trading its shares ahead of the formal annual results announcement due by the end of March 2026.

The most recent analyst rating on (HK:3737) stock is a Buy with a HK$0.80 price target. To see the full list of analyst forecasts on Zhongzhi Pharmaceutical Holdings Limited stock, see the HK:3737 Stock Forecast page.